Download PDF
Z Gastroenterol 2019; 57(12): 1493-1513
DOI: 10.1055/a-1013-4279
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Neuroendokrine Tumoren in der täglichen gastroenterologischen und endoskopischen Praxis – ein klinisch orientierter Leitfaden

Neuroendocrine tumors in daily gastroenterology and endoscopy – a practice manual
Walter Spindelböck
1   Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Graz, Austria
,
Patrizia Katharina Kump
1   Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Graz, Austria
,
Andreas Püspök
2   Abteilung für Innere Medizin II, Krankenhaus Barmherzige Brüder Eisenstadt, Austria
,
Robert Koch
3   Universitätsklinik für Innere Medizin I, Medizinische Universität Innsbruck, Austria
,
Marius Mayerhöfer
4   Universitätsklinik für Radiologie und Nuklearmedizin, Medizinische Universität Wien, Austria
,
Alexander Haug
4   Universitätsklinik für Radiologie und Nuklearmedizin, Medizinische Universität Wien, Austria
,
Eva Fritz
5   Abteilung für Innere Medizin I, Klinikum Wels – Grieskirchen GmbH, Wels, Austria
,
Barbara Obermayer-Pietsch
6   Klinische Abteilung für Endokrinologie und Diabetologie, Medizinische Universität Graz, Austria
,
Markus Raderer
7   Klinische Abteilung für Onkologie, Medizinische Universität Wien, Austria
,
Barbara Tribl
8   Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Wien, Austria
› Author Affiliations
Further Information

Publication History

13 December 2018

10 September 2019

Publication Date:
11 December 2019 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Neuroendokrine Tumoren des Gastrointestinaltrakts (GI-NET) sind selten. Die im Vergleich zu den mit hormonellen Syndromen assoziierten funktionellen Tumoren (Insulinom, Gastrinom) häufigeren nichtfunktionellen Tumoren verlaufen klinisch in der Regel bis in späte Stadien indolent. Die Therapie der GI-NET ist multimodal, wobei kurative Therapieansätze aus der vollständigen Entfernung des Tumorgewebes auf endoskopischem respektive chirurgischem Weg bestehen. Patienten in späten Tumorstadien profitieren von interventionell-radiologischen oder medikamentösen Therapieverfahren. Der vorliegende Artikel gibt einen praxisnahen Überblick über die Schlüsselaspekte der Therapie von gastrointestinalen NET in der täglichen gastroenterologischen Praxis mit Schwerpunkt auf endoskopischen Diagnose- und Therapieverfahren.

Abstract

Neuroendocrine tumors of the gastrointestinal tract (GI-NET) are rare tumors. Functional tumors with hormonal syndromes (e. g., insulinoma, gastrinoma) are less common than non-functional tumors, which usually have an indolent course. Therapy for GI-NET is multimodal, including endoscopic or surgical procedures aiming at complete removal of tumor tissue. Patients in later stages may benefit from interventional radiology or medical therapy. This article gives an overview regarding the key aspects of GI-NET therapy in daily gastroenterology practice with emphasis on endoscopic diagnosis and therapy.

Schlüsselwörter

Gastro-entero-pankreatische Tumoren - atrophische Gastritis/Typ-A-Gastritis - Insulinom - Gastrinom

Key words

gastro-entero-pancreatic tumors - atrophic gastritis/Type A-gastritis - insulinoma - gastrinoma
 

  • Literatur

  • 1 Bosman FT, Carneiro F, Hruban RH. et al. WHO classification of tumours of the digestive system. World Health Organization; 2010
    PubMedGoogle Scholar
  • 2 Lloyd ROR, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. Lyon, France: International Agency for Research on Cancer (IARC); 2017 4.. Aufl.
    PubMedGoogle Scholar
  • 3 Oberndorfer S. Karzinoide Tumoren des Duenndarmes. Frank Z Pathol 1907; 1: 426-429
    PubMedGoogle Scholar
  • 4 Dasari A, Shen C, Halperin D. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3: 1335-1342 . doi:10.1001/jamaoncol.2017.0589
    CrossrefPubMedGoogle Scholar
  • 5 Niederle MB, Hackl M, Kaserer K. et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocrine-related cancer 2010; 17: 909-918 . doi:10.1677/ERC-10-0152
    CrossrefPubMedGoogle Scholar
  • 6 Brierley JGM, Wittekind C. TNM classification of malignant tumours. 8.. Aufl. Chichester, West Sussex, UK; Hoboken, NJ: John Wiley & Sons, Inc; 2017
    Google Scholar
  • 7 https://www.enets.org/1516752000055.d.f.426.pdf
    PubMed
  • 8 Teo RYA, Teo TZ, Tai DWM. et al. Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms. Surgery 2019; 165: 672-685 . doi:10.1016/j.surg.2018.10.031
    CrossrefPubMedGoogle Scholar
  • 9 Clift AK, Faiz O, Goldin R. et al. Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocrine connections 2017; 6: 71-81 . doi:10.1530/EC-16-0114
    CrossrefPubMedGoogle Scholar
  • 10 Kloppel G. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. Visc Med 2017; 33: 324-330 . doi:10.1159/000481390
    CrossrefPubMedGoogle Scholar
  • 11 Kloppel G, Couvelard A, Perren A. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90: 162-166 . doi:10.1159/000182196
    CrossrefPubMedGoogle Scholar
  • 12 Oberg K, Knigge U, Kwekkeboom D. et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2012; 23 (Suppl. 07) vii124-vii130 . doi:10.1093/annonc/mds295
    CrossrefPubMedGoogle Scholar
  • 13 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13715 carcinoid tumors. Cancer 2003; 97: 934-959 . doi:10.1002/cncr.11105
    CrossrefPubMedGoogle Scholar
  • 14 Kamp K, Damhuis RA, Feelders RA. et al. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. Endocrine-related cancer 2012; 19: 95-99 . doi:10.1530/ERC-11-0315
    PubMedGoogle Scholar
  • 15 Clift AK, Drymousis P, Al-Nahhas A. et al. Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours. Neuroendocrinology 2015; 102: 26-32 . doi:10.1159/000381716
    CrossrefPubMedGoogle Scholar
  • 16 Caplin ME, Buscombe JR, Hilson AJ. et al. Carcinoid tumour. Lancet 1998; 352: 799-805 . doi:10.1016/S0140-6736(98)02286-7
    CrossrefPubMedGoogle Scholar
  • 17 Bornschein J, Kidd M, Malfertheiner P. et al. Gastrointestinal neuroendocrine tumors. Deutsche medizinische Wochenschrift 2008; 133: 1505-1510 . doi:10.1055/s-2008-1081099
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid Heart Disease: From Pathophysiology to Treatment – „Something in the Way It Moves“. Neuroendocrinology 2015; 101: 263-273 . doi:10.1159/000381930
    CrossrefPubMedGoogle Scholar
  • 19 Schott M, Kloppel G, Raffel A. et al. Neuroendocrine neoplasms of the gastrointestinal tract. Deutsches Arzteblatt international 2011; 108: 305-312 . doi:10.3238/arztebl.2011.0305
    PubMedGoogle Scholar
  • 20 Berna MJ, Annibale B, Marignani M. et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. The Journal of clinical endocrinology and metabolism 2008; 93: 1582-1591 . doi:10.1210/jc.2007-2279
    CrossrefPubMedGoogle Scholar
  • 21 Mosli HH, Dennis A, Kocha W. et al. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. The Journal of clinical endocrinology and metabolism 2012; 97: E1731-E1735 . doi:10.1210/jc.2012-1548
    CrossrefPubMedGoogle Scholar
  • 22 Turner JJ, Christie PT, Pearce SH. et al. Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). Human mutation 2010; 31: E1089-E1101 . doi:10.1002/humu.21170
    CrossrefPubMedGoogle Scholar
  • 23 Brandi ML, Gagel RF, Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. The Journal of clinical endocrinology and metabolism 2001; 86: 5658-5671 . doi:10.1210/jcem.86.12.8070
    CrossrefPubMedGoogle Scholar
  • 24 El SaghirNS, Keating NL, Carlson RW. et al. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book 2014; DOI: 10.14694/EdBook_AM.2014.34.e461.
    CrossrefPubMedGoogle Scholar
  • 25 Holzer K. Gastroenteropancreatic neuroendocrine tumors: targeted diagnostics and therapy. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 2014; 85: 731-744 . doi:10.1007/s00104-013-2679-5
    CrossrefPubMedGoogle Scholar
  • 26 Deutsche Gesellschaft fur Gastroenterologie V-uS, Netzwerk Neuroendokrine Tumoren e. V., Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e. V. et al. Practice guideline neuroendocrine tumors – AWMF-Reg. 021-27. Z Gastroenterol 2018; 56: 583-681 . doi:10.1055/a-0604-2924
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Campana D, Ravizza D, Ferolla P. et al. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine 2016; DOI: 10.1007/s12020-016-1099-y.
    CrossrefPubMedGoogle Scholar
  • 28 Thomas D, Tsolakis AV, Grozinsky-Glasberg S. et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. European journal of endocrinology/European Federation of Endocrine Societies 2013; 168: 185-193 . doi:10.1530/EJE-12-0836
    CrossrefPubMedGoogle Scholar
  • 29 Grozinsky-Glasberg S, Thomas D, Strosberg JR. et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth?. World journal of gastroenterology 2013; 19: 8687-8695 . doi:10.3748/wjg.v19.i46.8687
    CrossrefPubMedGoogle Scholar
  • 30 La Rosa S, Inzani F, Vanoli A. et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Human pathology 2011; 42: 1373-1384 . doi:10.1016/j.humpath.2011.01.018
    CrossrefPubMedGoogle Scholar
  • 31 Delle Fave G, Kwekkeboom DJ, Van Cutsem E. et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95: 74-87 . doi:10.1159/000335595
    CrossrefPubMedGoogle Scholar
  • 32 Dixon MF, Genta RM, Yardley JH. et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. The American journal of surgical pathology 1996; 20: 1161-1181
    PubMedGoogle Scholar
  • 33 Basuroy R, Srirajaskanthan R, Prachalias A. et al. Review article: the investigation and management of gastric neuroendocrine tumours. Alimentary pharmacology & therapeutics 2014; 39: 1071-1084 . doi:10.1111/apt.12698
    CrossrefPubMedGoogle Scholar
  • 34 Hasegawa S, Kobayashi N, Tokuhisa M. et al. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors. Digestion 2017; 96: 13-20 . doi:10.1159/000470838
    CrossrefPubMedGoogle Scholar
  • 35 Morgat C, Velayoudom-Cephise FL, Schwartz P. et al. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. European journal of nuclear medicine and molecular imaging 2016; 43: 1258-1266 . doi:10.1007/s00259-016-3319-3
    CrossrefPubMedGoogle Scholar
  • 36 Merola E, Sbrozzi-Vanni A, Panzuto F. et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012; 95: 207-213 . doi:10.1159/000329043
    CrossrefPubMedGoogle Scholar
  • 37 Uygun A, Kadayifci A, Polat Z. et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. Journal of surgical oncology 2014; 109: 71-74 . doi:10.1002/jso.23477
    CrossrefPubMedGoogle Scholar
  • 38 Li QL, Zhang YQ, Chen WF. et al. Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World journal of gastroenterology 2012; 18: 5799-5806 . doi:10.3748/wjg.v18.i40.5799
    CrossrefPubMedGoogle Scholar
  • 39 Campana D, Ravizza D, Ferolla P. et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine 2016; 51: 131-139 . doi:10.1007/s12020-015-0584-z
    CrossrefPubMedGoogle Scholar
  • 40 Sato Y, Imamura H, Kaizaki Y. et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Digestive endoscopy: official journal of the Japan Gastroenterological Endoscopy Society 2014; 26: 377-384 . doi:10.1111/den.12197
    PubMedGoogle Scholar
  • 41 Sato Y, Takeuchi M, Hashimoto S. et al. Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection. Hepato-gastroenterology 2013; 60: 1524-1529 . doi:10.5754/hge121185
    PubMedGoogle Scholar
  • 42 Sarker S, Gutierrez JP, Council L. et al. Over-the-scope clip-assisted method for resection of full-thickness submucosal lesions of the gastrointestinal tract. Endoscopy 2014; 46: 758-761 . doi:10.1055/s-0034-1365513
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Delle Fave G, O’Toole D, Sundin A. et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology 2016; 103: 119-124 . doi:10.1159/000443168
    CrossrefPubMedGoogle Scholar
  • 44 Kulke MH, Shah MH, Benson AB. et al. Neuroendocrine tumors, version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN 2015; 13: 78-108
    PubMedGoogle Scholar
  • 45 Falconi M, Eriksson B, Kaltsas G. et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016; 103: 153-171 . doi:10.1159/000443171
    CrossrefPubMedGoogle Scholar
  • 46 Waddell T, Verheij M, Allum W. et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2013; 24 (Suppl. 06) vi57-vi63 . doi:10.1093/annonc/mdt344
    CrossrefPubMedGoogle Scholar
  • 47 Fykse V, Sandvik AK, Qvigstad G. et al. Treatment of ECL cell carcinoids with octreotide LAR. Scandinavian journal of gastroenterology 2004; 39: 621-628 . doi:10.1080/00365520410005225
    CrossrefPubMedGoogle Scholar
  • 48 Fykse V, Sandvik AK, Waldum HL. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scandinavian journal of gastroenterology 2005; 40: 1269-1274
    CrossrefPubMedGoogle Scholar
  • 49 Jianu CS, Fossmark R, Syversen U. et al. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scandinavian journal of gastroenterology 2011; 46: 456-463 . doi:10.3109/00365521.2010.539255
    CrossrefPubMedGoogle Scholar
  • 50 Khuroo MS, Khuroo MS, Khuroo NS. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. Journal of gastroenterology and hepatology 2010; 25: 548-554 . doi:10.1111/j.1440-1746.2009.06131.x
    CrossrefPubMedGoogle Scholar
  • 51 Garcia-Carbonero R, Sorbye H, Baudin E. et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 2016; 103: 186-194 . doi:10.1159/000443172
    CrossrefPubMedGoogle Scholar
  • 52 Scherubl H, Jensen RT, Cadiot G. et al. Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World journal of gastrointestinal endoscopy 2010; 2: 325-334 . doi:10.4253/wjge.v2.i10.325
    CrossrefPubMedGoogle Scholar
  • 53 Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best practice & research Clinical gastroenterology 2005; 19: 675-697 . doi:10.1016/j.bpg.2005.05.009
    CrossrefPubMedGoogle Scholar
  • 54 Gincul R, Ponchon T, Napoleon B. et al. Endoscopic treatment of sporadic small duodenal and ampullary neuroendocrine tumors. Endoscopy 2016; DOI: 10.1055/s-0042-112570.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Donow C, Pipeleers-Marichal M, Schroder S. et al. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer 1991; 68: 1329-1334
    CrossrefPubMedGoogle Scholar
  • 56 Randle RW, Ahmed S, Newman NA. et al. Clinical outcomes for neuroendocrine tumors of the duodenum and ampulla of Vater: a population-based study. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 2014; 18: 354-362 . doi:10.1007/s11605-013-2365-4
    CrossrefPubMedGoogle Scholar
  • 57 Vanoli A, La Rosa S, Klersy C. et al. Four Neuroendocrine Tumor Types and the Neuroendocrine Carcinoma of the Duodenum. Analysis of 203 Cases. Neuroendocrinology 2016; DOI: 10.1159/000444803.
    CrossrefPubMedGoogle Scholar
  • 58 Sadowski SM, Neychev V, Millo C. et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016; 34: 588-596 . doi:10.1200/JCO.2015.64.0987
    PubMedGoogle Scholar
  • 59 Kim GH, Kim JI, Jeon SW. et al. Endoscopic resection for duodenal carcinoid tumors: a multicenter, retrospective study. Journal of gastroenterology and hepatology 2014; 29: 318-324 . doi:10.1111/jgh.12390
    CrossrefPubMedGoogle Scholar
  • 60 Kyuno D, Ohno K, Katsuki S. et al. Laparoscopic-endoscopic cooperative surgery is a safe and effective treatment for superficial nonampullary duodenal tumors. Asian J Endosc Surg 2015; 8: 461-464 . doi:10.1111/ases.12211
    CrossrefPubMedGoogle Scholar
  • 61 Pape UF, Maasberg S, Jann H. et al. Management of follow-up of neuroendocrine neoplasias. Best practice & research Clinical endocrinology & metabolism 2016; 30: 129-140 . doi:10.1016/j.beem.2016.02.001
    CrossrefPubMedGoogle Scholar
  • 62 Haug AR, Cindea-Drimus R, Auernhammer CJ. et al. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology 2014; 270: 517-525 . doi:10.1148/radiol.13122501
    CrossrefPubMedGoogle Scholar
  • 63 de Herder WW, Niederle B, Scoazec JY. et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 183-188 . doi:10.1159/000098010
    CrossrefPubMedGoogle Scholar
  • 64 Jensen RT, Niederle B, Mitry E. et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173-182 . doi:10.1159/000098009
    CrossrefPubMedGoogle Scholar
  • 65 O’Toole D, Salazar R, Falconi M. et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006; 84: 189-195 . doi:10.1159/000098011
    CrossrefPubMedGoogle Scholar
  • 66 Thomas-Marques L, Murat A, Delemer B. et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. The American journal of gastroenterology 2006; 101: 266-273 . doi:10.1111/j.1572-0241.2006.00367.x
    CrossrefPubMedGoogle Scholar
  • 67 Rosch T, Lightdale CJ, Botet JF. et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. The New England journal of medicine 1992; 326: 1721-1726 . doi:10.1056/NEJM199206253262601
    CrossrefPubMedGoogle Scholar
  • 68 Anderson MA, Carpenter S, Thompson NW. et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. The American journal of gastroenterology 2000; 95: 2271-2277 . doi:10.1111/j.1572-0241.2000.02480.x
    CrossrefPubMedGoogle Scholar
  • 69 Dietrich CF, Sahai AV, D’Onofrio M. et al. Differential diagnosis of small solid pancreatic lesions. Gastrointestinal endoscopy 2016; DOI: 10.1016/j.gie.2016.04.034.
    CrossrefPubMedGoogle Scholar
  • 70 Kitano M, Kudo M, Yamao K. et al. Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography. The American journal of gastroenterology 2012; 107: 303-310 . doi:10.1038/ajg.2011.354
    CrossrefPubMedGoogle Scholar
  • 71 Bang JY, Hebert-Magee S, Trevino J. et al. Randomized trial comparing the 22-gauge aspiration and 22-gauge biopsy needles for EUS-guided sampling of solid pancreatic mass lesions. Gastrointestinal endoscopy 2012; 76: 321-327 . doi:10.1016/j.gie.2012.03.1392
    CrossrefPubMedGoogle Scholar
  • 72 Ramesh J, Bang JY, Hebert-Magee S. et al. Randomized Trial Comparing the Flexible 19G and 25G Needles for Endoscopic Ultrasound-Guided Fine Needle Aspiration of Solid Pancreatic Mass Lesions. Pancreas 2015; 44: 128-133 . doi:10.1097/MPA.0000000000000217
    CrossrefPubMedGoogle Scholar
  • 73 Weynand B, Borbath I, Bernard V. et al. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index. Cytopathology: official journal of the British Society for Clinical Cytology 2014; 25: 389-395 . doi:10.1111/cyt.12111
    PubMedGoogle Scholar
  • 74 Chantarojanasiri T, Hirooka Y, Kawashima H. et al. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone versus the combination. Endoscopy international open 2017; 5: E1136-E1143 . doi:10.1055/s-0043-118829
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 van Asselt SJ, Brouwers AH, van Dullemen HM. et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointestinal endoscopy 2015; 81: 159-167 e152 . doi:10.1016/j.gie.2014.09.037
    CrossrefPubMedGoogle Scholar
  • 76 Tamagno G, Scherer V, Caimo A. et al. Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study. Digestion 2018; 98: 112-118 . doi:10.1159/000487939
    CrossrefPubMedGoogle Scholar
  • 77 Qiu W, Christakis I, Silva A. et al. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clinical endocrinology 2016; 85: 400-407 . doi:10.1111/cen.13119
    CrossrefPubMedGoogle Scholar
  • 78 Sundin A, Vullierme MP, Kaltsas G. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-183 . doi:10.1159/000184855
    CrossrefPubMedGoogle Scholar
  • 79 Sharma P, Arora S, Dhull VS. et al. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Abdominal imaging 2015; 40: 299-309 . doi:10.1007/s00261-014-0219-5
    CrossrefPubMedGoogle Scholar
  • 80 Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN. et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. European journal of nuclear medicine and molecular imaging 2013; 40: 897-907 . doi:10.1007/s00259-013-2371-5
    CrossrefPubMedGoogle Scholar
  • 81 Hoeffel C, Job L, Ladam-Marcus V. et al. Detection of hepatic metastases from carcinoid tumor: prospective evaluation of contrast-enhanced ultrasonography. Digestive diseases and sciences 2009; 54: 2040-2046 . doi:10.1007/s10620-008-0570-x
    CrossrefPubMedGoogle Scholar
  • 82 Park H, Choi JH, Oh D. et al. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study. Clinical endoscopy 2015; 48: 158-164 . doi:10.5946/ce.2015.48.2.158
    CrossrefPubMedGoogle Scholar
  • 83 Armellini E, Crino SF, Ballare M. et al. Endoscopic ultrasound-guided ethanol ablation of pancreatic neuroendocrine tumours: A case study and literature review. World journal of gastrointestinal endoscopy 2016; 8: 192-197 . doi:10.4253/wjge.v8.i3.192
    CrossrefPubMedGoogle Scholar
  • 84 Rossi S, Viera FT, Ghittoni G. et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas 2014; 43: 938-945 . doi:10.1097/MPA.0000000000000133
    CrossrefPubMedGoogle Scholar
  • 85 Pai M, Habib N, Senturk H. et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World journal of gastrointestinal surgery 2015; 7: 52-59 . doi:10.4240/wjgs.v7.i4.52
    CrossrefPubMedGoogle Scholar
  • 86 Sallinen V, Le Large TY, Galeev S. et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors – a systematic review and meta-analysis. HPB (Oxford) 2017; 19: 310-320 . doi:10.1016/j.hpb.2016.12.010
    CrossrefPubMedGoogle Scholar
  • 87 Raymond E, Dahan L, Raoul JL. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England journal of medicine 2011; 364: 501-513 . doi:10.1056/NEJMoa1003825
    CrossrefPubMedGoogle Scholar
  • 88 Yao JC, Shah MH, Ito T. et al. Everolimus for advanced pancreatic neuroendocrine tumors. The New England journal of medicine 2011; 364: 514-523 . doi:10.1056/NEJMoa1009290
    CrossrefPubMedGoogle Scholar
  • 89 Pavel M, O’Toole D, Costa F. et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016; 103: 172-185 . doi:10.1159/000443167
    CrossrefPubMedGoogle Scholar
  • 90 Mehrabi A, Fischer L, Hafezi M. et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 2014; 43: 675-686 . doi:10.1097/MPA.0000000000000110
    CrossrefPubMedGoogle Scholar
  • 91 McLean AM, Fairclough PD. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best practice & research Clinical endocrinology & metabolism 2005; 19: 177-193 . doi:10.1016/j.beem.2004.11.012
    CrossrefPubMedGoogle Scholar
  • 92 Sotoudehmanesh R, Hedayat A, Shirazian N. et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine 2007; 31: 238-241
    CrossrefPubMedGoogle Scholar
  • 93 Kann PH, Moll R, Bartsch D. et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: Indications and clinical relevance in a single investigator cohort of 47 patients. Endocrine 2017; 56: 158-163 . doi:10.1007/s12020-016-1179-z
    CrossrefPubMedGoogle Scholar
  • 94 Jensen RT, Cadiot G, Brandi ML. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119 . doi:10.1159/000335591
    CrossrefPubMedGoogle Scholar
  • 95 Nockel P, Babic B, Millo C. et al. Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan. The Journal of clinical endocrinology and metabolism 2017; 102: 195-199 . doi:10.1210/jc.2016-3445
    CrossrefPubMedGoogle Scholar
  • 96 Prasad V, Sainz-Esteban A, Arsenic R. et al. Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. European journal of nuclear medicine and molecular imaging 2016; 43: 1593-1600 . doi:10.1007/s00259-016-3331-7
    CrossrefPubMedGoogle Scholar
  • 97 Kauhanen S, Seppanen M, Minn H. et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. The Journal of clinical endocrinology and metabolism 2007; 92: 1237-1244 . doi:10.1210/jc.2006-1479
    CrossrefPubMedGoogle Scholar
  • 98 Wild D, Macke H, Christ E. et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. The New England journal of medicine 2008; 359: 766-768 . doi:10.1056/NEJMc0802045
    CrossrefPubMedGoogle Scholar
  • 99 Luo Y, Pan Q, Yao S. et al. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2016; 57: 715-720 . doi:10.2967/jnumed.115.167445
    PubMedGoogle Scholar
  • 100 Lin XZ, Wu ZY, Tao R. et al. Dual energy spectral CT imaging of insulinoma-Value in preoperative diagnosis compared with conventional multi-detector CT. European journal of radiology 2012; 81: 2487-2494 . doi:10.1016/j.ejrad.2011.10.028
    CrossrefPubMedGoogle Scholar
  • 101 Lakhtakia S, Ramchandani M, Galasso D. et al. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointestinal endoscopy 2016; 83: 234-239 . doi:10.1016/j.gie.2015.08.085
    CrossrefPubMedGoogle Scholar
  • 102 Qin SY, Lu XP, Jiang HX. EUS-guided ethanol ablation of insulinomas: case series and literature review. Medicine 2014; 93: e85 . doi:10.1097/MD.0000000000000085
    PubMedGoogle Scholar
  • 103 Jann H, Roll S, Couvelard A. et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117: 3332-3341 . doi:10.1002/cncr.25855
    CrossrefPubMedGoogle Scholar
  • 104 Niederle MB, Niederle B. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. The oncologist 2011; 16: 602-613 . doi:10.1634/theoncologist.2011-0002
    CrossrefPubMedGoogle Scholar
  • 105 Bellutti M, Fry LC, Schmitt J. et al. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Digestive diseases and sciences 2009; 54: 1050-1058 . doi:10.1007/s10620-008-0456-y
    CrossrefPubMedGoogle Scholar
  • 106 Pennazio M, Spada C, Eliakim R. et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2015; 47: 352-376 . doi:10.1055/s-0034-1391855
    Article in Thieme ConnectPubMedGoogle Scholar
  • 107 Zagorowicz ES, Pietrzak AM, Wronska E. et al. Small bowel tumors detected and missed during capsule endoscopy: single center experience. World journal of gastroenterology 2013; 19: 9043-9048 . doi:10.3748/wjg.v19.i47.9043
    CrossrefPubMedGoogle Scholar
  • 108 Frilling A, Smith G, Clift AK. et al. Capsule endoscopy to detect primary tumour site in metastatic neuroendocrine tumours. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2014; 46: 1038-1042 . doi:10.1016/j.dld.2014.07.004
    CrossrefPubMedGoogle Scholar
  • 109 Singeap AM, Trifan A, Cojocariu C. et al. Outcomes after symptomatic capsule retention in suspected small bowel obstruction. European journal of gastroenterology & hepatology 2011; 23: 886-890 . doi:10.1097/MEG.0b013e328349efa4
    CrossrefPubMedGoogle Scholar
  • 110 Rossi RE, Conte D, Elli L. et al. Endoscopic techniques to detect small-bowel neuroendocrine tumors: A literature review. United European gastroenterology journal 2017; 5: 5-12 . doi:10.1177/2050640616658220
    CrossrefPubMedGoogle Scholar
  • 111 Cangemi DJ, Patel MK, Gomez V. et al. Small bowel tumors discovered during double.balloon enteroscopy: analysis of a large prospectively collected single-center database. J Clin Gastroenterol 2013; 47: 769-772 . doi:10.1097/MCG.0b013e318281a44e
    CrossrefPubMedGoogle Scholar
  • 112 Arnold R, Wilke A, Rinke A. et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2008; 6: 820-827 . doi:10.1016/j.cgh.2008.02.052
    CrossrefPubMedGoogle Scholar
  • 113 Pape UF, Perren A, Niederle B. et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95: 135-156 . doi:10.1159/000335629
    CrossrefPubMedGoogle Scholar
  • 114 Niederle B, Pape UF, Costa F. et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016; 103: 125-138 . doi:10.1159/000443170
    CrossrefPubMedGoogle Scholar
  • 115 Ardill JE, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocrine-related cancer 2003; 10: 459-462
    PubMedGoogle Scholar
  • 116 Feldman JM, O’Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. The American journal of medicine 1986; 81: 41-48
    CrossrefPubMedGoogle Scholar
  • 117 Bhattacharyya S, Toumpanakis C, Caplin ME. et al. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. The American journal of cardiology 2008; 102: 938-942 . doi:10.1016/j.amjcard.2008.05.047
    CrossrefPubMedGoogle Scholar
  • 118 Arnold R, Chen YJ, Costa F. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90: 227-233 . doi:10.1159/000225952
    CrossrefPubMedGoogle Scholar
  • 119 Baum RP, Prasad V, Hommann M. et al. Receptor PET/CT imaging of neuroendocrine tumors. Recent results in cancer research. Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2008; 170: 225-242
    PubMedGoogle Scholar
  • 120 Kulemann V, Schima W, Tamandl D. et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?. European journal of radiology 2011; 79: e1-e6 . doi:10.1016/j.ejrad.2010.03.004
    PubMedGoogle Scholar
  • 121 Mayerhoefer ME, Ba-Ssalamah A, Weber M. et al. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. European radiology 2013; 23: 1978-1985 . doi:10.1007/s00330-013-2785-2
    CrossrefPubMedGoogle Scholar
  • 122 Berzaczy D, Giraudo C, Haug AR. et al. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clinical nuclear medicine 2017; 42: 669-674 . doi:10.1097/RLU.0000000000001753
    CrossrefPubMedGoogle Scholar
  • 123 Landerholm K, Zar N, Andersson RE. et al. Survival and prognostic factors in patients with small bowel carcinoid tumour. The British journal of surgery 2011; 98: 1617-1624 . doi:10.1002/bjs.7649
    CrossrefPubMedGoogle Scholar
  • 124 Landry CS, Lin HY, Phan A. et al. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World journal of surgery 2013; 37: 1695-1700 . doi:10.1007/s00268-013-1918-8
    CrossrefPubMedGoogle Scholar
  • 125 Schindl M, Kaczirek K, Passler C. et al. Treatment of small intestinal neuroendocrine tumors: is an extended multimodal approach justified?. World journal of surgery 2002; 26: 976-984 . doi:10.1007/s00268-002-6628-6
    CrossrefPubMedGoogle Scholar
  • 126 Capurso G, Rinzivillo M, Bettini R. et al. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. The British journal of surgery 2012; 99: 1480-1486 . doi:10.1002/bjs.8842
    CrossrefPubMedGoogle Scholar
  • 127 Rinke A, Wittenberg M, Schade-Brittinger C. et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology 2017; 104: 26-32 . doi:10.1159/000443612
    CrossrefPubMedGoogle Scholar
  • 128 Caplin ME, Pavel M, Cwikla JB. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. The New England journal of medicine 2014; 371: 224-233 . doi:10.1056/NEJMoa1316158
    CrossrefPubMedGoogle Scholar
  • 129 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England journal of medicine 2017; 376: 125-135 . doi:10.1056/NEJMoa1607427
    CrossrefPubMedGoogle Scholar
  • 130 Yao JC, Fazio N, Singh S. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968-977 . doi:10.1016/S0140-6736(15)00817-X
    CrossrefPubMedGoogle Scholar
  • 131 Pape UF, Berndt U, Muller-Nordhorn J. et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-related cancer 2008; 15: 1083-1097 . doi:10.1677/ERC-08-0017
    CrossrefPubMedGoogle Scholar
  • 132 Modlin IM, Kidd M, Latich I. et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751
    CrossrefPubMedGoogle Scholar
  • 133 Alexandraki KI, Kaltsas GA, Grozinsky-Glasberg S. et al. Appendiceal neuroendocrine neoplasms: diagnosis and management. Endocrine-related cancer 2016; 23: R27-R41 . doi:10.1530/ERC-15-0310
    CrossrefPubMedGoogle Scholar
  • 134 Rossi RE, Luong TV, Caplin ME. et al. Goblet cell appendiceal tumors--management dilemmas and long-term outcomes. Surgical oncology 2015; 24: 47-53 . doi:10.1016/j.suronc.2015.01.001
    CrossrefPubMedGoogle Scholar
  • 135 Toumpanakis C, Standish RA, Baishnab E. et al. Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. Diseases of the colon and rectum 2007; 50: 315-322 . doi:10.1007/s10350-006-0762-4
    CrossrefPubMedGoogle Scholar
  • 136 Pape UF, Niederle B, Costa F. et al. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology 2016; 103: 144-152 . doi:10.1159/000443165
    CrossrefPubMedGoogle Scholar
  • 137 Kleiman DA, Finnerty B, Beninato T. et al. Features Associated With Metastases Among Well-Differentiated Neuroendocrine (Carcinoid) Tumors of the Appendix: The Significance of Small Vessel Invasion in Addition to Size. Diseases of the colon and rectum 2015; 58: 1137-1143 . doi:10.1097/DCR.0000000000000492
    CrossrefPubMedGoogle Scholar
  • 138 Masselli G, Gualdi G. CT and MR enterography in evaluating small bowel diseases: when to use which modality?. Abdominal imaging 2013; 38: 249-259 . doi:10.1007/s00261-012-9961-8
    CrossrefPubMedGoogle Scholar
  • 139 Caplin M, Sundin A, Nillson O. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012; 95: 88-97 . doi:10.1159/000335594
    CrossrefPubMedGoogle Scholar
  • 140 Murray SE, Lloyd RV, Sippel RS. et al. Clinicopathologic characteristics of colonic carcinoid tumors. The Journal of surgical research 2013; 184: 183-188 . doi:10.1016/j.jss.2013.05.107
    CrossrefPubMedGoogle Scholar
  • 141 Al Natour RH, Saund MS, Sanchez VM. et al. Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 2012; 16: 595-602 . doi:10.1007/s11605-011-1786-1
    CrossrefPubMedGoogle Scholar
  • 142 Salyers WJ, Vega KJ, Munoz JC. et al. Neuroendocrine tumors of the gastrointestinal tract: Case reports and literature review. World journal of gastrointestinal oncology 2014; 6: 301-310 . doi:10.4251/wjgo.v6.i8.301
    CrossrefPubMedGoogle Scholar
  • 143 Ramage JK, De Herder WW, Delle Fave G. et al. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology 2016; 103: 139-143 . doi:10.1159/000443166
    CrossrefPubMedGoogle Scholar
  • 144 Kunz PL, Reidy-Lagunes D, Anthony LB. et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013; 42: 557-577 . doi:10.1097/MPA.0b013e31828e34a4
    CrossrefPubMedGoogle Scholar
  • 145 Hope TA, Pampaloni MH, Nakakura E. et al. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdominal imaging 2015; 40: 1432-1440 . doi:10.1007/s00261-015-0409-9
    CrossrefPubMedGoogle Scholar
  • 146 Caplin ME, Pavel M, Cwikla JB. et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocrine-related cancer 2016; 23: 191-199 . doi:10.1530/ERC-15-0490
    CrossrefPubMedGoogle Scholar
  • 147 Janson ET, Sorbye H, Welin S. et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta oncologica 2014; 53: 1284-1297 . doi:10.3109/0284186X.2014.941999
    CrossrefPubMedGoogle Scholar
  • 148 Jetmore AB, Ray JE, Gathright Jr JB. et al. Rectal carcinoids: the most frequent carcinoid tumor. Diseases of the colon and rectum 1992; 35: 717-725
    CrossrefPubMedGoogle Scholar
  • 149 Chi Y, Du F, Zhao H. et al. Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors. World journal of gastroenterology 2014; 20: 16252-16257 . doi:10.3748/wjg.v20.i43.16252
    CrossrefPubMedGoogle Scholar
  • 150 Jernman J, Valimaki MJ, Louhimo J. et al. The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours. Neuroendocrinology 2012; 95: 317-324 . doi:10.1159/000333035
    CrossrefPubMedGoogle Scholar
  • 151 Higaki S, Nishiaki M, Mitani N. et al. Effectiveness of local endoscopic resection of rectal carcinoid tumors. Endoscopy 1997; 29: 171-175 . doi:10.1055/s-2007-1004158
    Article in Thieme ConnectPubMedGoogle Scholar
  • 152 Lee SP, Sung IK, Kim JH. et al. The effect of preceding biopsy on complete endoscopic resection in rectal carcinoid tumor. Journal of Korean medical science 2014; 29: 512-518 . doi:10.3346/jkms.2014.29.4.512
    CrossrefPubMedGoogle Scholar
  • 153 Kobayashi K, Katsumata T, Yoshizawa S. et al. Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. Diseases of the colon and rectum 2005; 48: 285-291 . doi:10.1007/s10350-004-0765-y
    CrossrefPubMedGoogle Scholar
  • 154 Kim JH, Moon W, Park SJ. et al. Clinical impact of endoscopic ultrasonography for small rectal neuroendocrine tumors. The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology 2014; 25: 657-660 . doi:10.5152/tjg.2014.6647
    PubMedGoogle Scholar
  • 155 Park CH, Cheon JH, Kim JO. et al. Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy 2011; 43: 790-795 . doi:10.1055/s-0030-1256414
    Article in Thieme ConnectPubMedGoogle Scholar
  • 156 Gleeson FC, Levy MJ, Dozois EJ. et al. Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes. Gastrointestinal endoscopy 2014; 80: 144-151 . doi:10.1016/j.gie.2013.11.031
    CrossrefPubMedGoogle Scholar
  • 157 Nasseri Y, Langenfeld SJ. Imaging for Colorectal Cancer. The Surgical clinics of North America 2017; 97: 503-513 . doi:10.1016/j.suc.2017.01.002
    CrossrefPubMedGoogle Scholar
  • 158 Basuroy R, Haji A, Ramage JK. et al. Review article: the investigation and management of rectal neuroendocrine tumours. Alimentary pharmacology & therapeutics 2016; 44: 332-345 . doi:10.1111/apt.13697
    CrossrefPubMedGoogle Scholar
  • 159 Zhou X, Xie H, Xie L. et al. Endoscopic resection therapies for rectal neuroendocrine tumors: a systematic review and meta-analysis. Journal of gastroenterology and hepatology 2014; 29: 259-268 . doi:10.1111/jgh.12395
    CrossrefPubMedGoogle Scholar
  • 160 Sung HY, Kim SW, Kang WK. et al. Long-term prognosis of an endoscopically treated rectal neuroendocrine tumor: 10-year experience in a single institution. European journal of gastroenterology & hepatology 2012; 24: 978-983 . doi:10.1097/MEG.0b013e3283551e0b
    CrossrefPubMedGoogle Scholar
  • 161 Park HW, Byeon JS, Park YS. et al. Endoscopic submucosal dissection for treatment of rectal carcinoid tumors. Gastrointestinal endoscopy 2010; 72: 143-149 . doi:10.1016/j.gie.2010.01.040
    CrossrefPubMedGoogle Scholar
  • 162 Lee DS, Jeon SW, Park SY. et al. The feasibility of endoscopic submucosal dissection for rectal carcinoid tumors: comparison with endoscopic mucosal resection. Endoscopy 2010; 42: 647-651 . doi:10.1055/s-0030-1255591
    Article in Thieme ConnectPubMedGoogle Scholar
  • 163 Jeon JH, Cheung DY, Lee SJ. et al. Endoscopic resection yields reliable outcomes for small rectal neuroendocrine tumors. Digestive endoscopy: official journal of the Japan Gastroenterological Endoscopy Society 2014; 26: 556-563 . doi:10.1111/den.12232
    PubMedGoogle Scholar
  • 164 Kim GU, Kim KJ, Hong SM. et al. Clinical outcomes of rectal neuroendocrine tumors </= 10 mm following endoscopic resection. Endoscopy 2013; 45: 1018-1023 . doi:10.1055/s-0033-1344860
    Article in Thieme ConnectPubMedGoogle Scholar
  • 165 Klare P, Burlefinger R, Neu B. et al. Over-the-scope clip-assisted endoscopic full-thickness resection after incomplete resection of a rectal neuroendocrine tumor. Endoscopy 2015; 47 (Suppl. 01) E47-E48 . doi:10.1055/s-0034-1391301
    Article in Thieme ConnectPubMedGoogle Scholar
  • 166 Weinstock B, Ward SC, Harpaz N. et al. Clinical and prognostic features of rectal neuroendocrine tumors. Neuroendocrinology 2013; 98: 180-187 . doi:10.1159/000355612
    CrossrefPubMedGoogle Scholar